Patents by Inventor David E. Gorcyca

David E. Gorcyca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150276737
    Abstract: Immunogenic compositions that include swine infertility and respiratory virus (“SRRS virus”) are provided herein. Also provided are kits for producing and using the immunogenic compositions. Vaccines and sera for treatment of SRRS, a method for producing the vaccine, methods for diagnosis of SRRS, and antibodies to the viral agent useful in diagnosis and treatment of SRRS are also provided. Swine infertility and respiratory virus is also referred to herein as Mystery Swine Disease (“MSD”).
    Type: Application
    Filed: August 13, 2007
    Publication date: October 1, 2015
    Inventors: James E. Collins, David A. Benfield, Danny W. Chladek, Louis L. Harris, David E. Gorcyca
  • Patent number: 8747859
    Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: June 10, 2014
    Assignees: The United States of America, as Represented by the Secretary of Agriculture, Boehringer Ingelheim Vetmedica, Inc.
    Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Mike Roof, Kelly Burkhart, David E. Gorcyca
  • Patent number: 8741309
    Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: June 3, 2014
    Assignees: The United States of America as represented by the Secretary of Agriculture, Boehringer Ingelheim Vetmedica, Inc.
    Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Mike Roof, Kelly Burkhart, David E. Gorcyca
  • Patent number: 8491916
    Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: July 23, 2013
    Assignees: The United States of America as represented by the Secretary of Agriculture, Boehringer Ingelheim Vetmedica, Inc.
    Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Mike Roof, Kelly Burkhart, David E. Gorcyca
  • Publication number: 20110104201
    Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.
    Type: Application
    Filed: February 20, 2009
    Publication date: May 5, 2011
    Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Mike Roof, Kelly Burkhart, David E. Gorcyca
  • Patent number: 7264804
    Abstract: The invention includes kits for producing and using immunogenic compositions that include swine infertility and respiratory virus. The invention also includes vaccines and sera for treatment of Mystery Swine Disease (MSD), a method for producing the vaccine, methods for diagnosis of MSD, a viral agent that will mimic “mystery swine disease” and antibodies to the viral agent useful in diagnosis and treatment of MSD. The serum contains mammalian antibodies which are effective in treating MSD.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: September 4, 2007
    Assignees: Boehringer Ingleheim Vetmedica, Inc., Regents of the University of Minnesota, South Dakota State University
    Inventors: James E. Collins, David A. Benfield, Danny W. Chladek, Louis L. Harris, David E. Gorcyca
  • Patent number: 7081342
    Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.
    Type: Grant
    Filed: September 3, 2003
    Date of Patent: July 25, 2006
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Kelly Burkhart, David E. Gorcyca, Mike Roof
  • Patent number: 6982160
    Abstract: The invention includes kits for producing and using immunogenic compositions that include swine infertility and respiratory virus. The invention also includes vaccines and sera for treatment of Mystery Swine Disease (MSD), a method for producing the vaccine, methods for diagnosis of MSD, a viral agent that will mimic “mystery swine disease” and antibodies to the viral agent useful in diagnosis and treatment of MSD. The serum contains mammalian antibodies which are effective in treating MSD.
    Type: Grant
    Filed: May 6, 2004
    Date of Patent: January 3, 2006
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: James E. Collins, David A. Benfield, Danny W. Chladek, Louis L. Harris, David E. Gorcyca
  • Patent number: 6855315
    Abstract: The invention includes a vaccine and sera for treatment of Mystery Swine Disease (MSD), a method for producing the vaccine, methods for diagnosis of MSD, a viral agent that will mimic “mystery swine disease” and antibodies to the viral agent useful in diagnosis and treatment of MSD. The serum contains mammalian antibodies which are effective in treating MSD.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: February 15, 2005
    Assignees: Regents of the University of Minnesota, South Dakota State University, Boehringer Ingelheim Vetmedica, Inc.
    Inventors: James E. Collins, David A. Benfield, Danny W. Chladek, Louis L. Harris, David E. Gorcyca
  • Publication number: 20040208899
    Abstract: The invention includes kits for producing and using immunogenic compositions that include swine infertility and respiratory virus. The invention also includes vaccines and sera for treatment of Mystery Swine Disease (MSD), a method for producing the vaccine, methods for diagnosis of MSD, a viral agent that will mimic “mystery swine disease” and antibodies to the viral agent useful in diagnosis and treatment of MSD. The serum contains mammalian antibodies which are effective in treating MSD.
    Type: Application
    Filed: May 6, 2004
    Publication date: October 21, 2004
    Applicant: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: James E. Collins, David A. Benfield, Danny W. Chladek, Louis L. Harris, David E. Gorcyca
  • Publication number: 20040087002
    Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.
    Type: Application
    Filed: September 3, 2003
    Publication date: May 6, 2004
    Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Kelly Burkhart, David E. Gorcyca, Mike Roof
  • Patent number: 6660513
    Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation.
    Type: Grant
    Filed: May 9, 2002
    Date of Patent: December 9, 2003
    Assignees: USDA, Boehringer Ingelheim Corp.
    Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Mike Roof, Kelly Burkhart, David E. Gorcyca
  • Patent number: 6641819
    Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.
    Type: Grant
    Filed: October 18, 2001
    Date of Patent: November 4, 2003
    Assignees: USDA, Boehringer Ingelheim Corp.
    Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Kelly Burkhart, David E. Gorcyca, Mike Roof
  • Publication number: 20030170269
    Abstract: The invention includes a vaccine and sera for treatment of Mystery Swine Disease (MSD), a method for producing the vaccine, methods for diagnosis of MSD, a viral agent that will mimic “mystery swine disease” and antibodies to the viral agent useful in diagnosis and treatment of MSD. The serum contains mammalian antibodies which are effective in treating MSD.
    Type: Application
    Filed: October 28, 2002
    Publication date: September 11, 2003
    Applicant: Boehringer Ingelheim Animal Health, Inc.
    Inventors: James E. Collins, David A. Benfield, Danny W. Chladek, Louis L. Harris, David E. Gorcyca
  • Publication number: 20030119170
    Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.
    Type: Application
    Filed: October 18, 2001
    Publication date: June 26, 2003
    Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Kelly Burkhart, David E. Gorcyca, Mike Roof
  • Publication number: 20030072771
    Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation.
    Type: Application
    Filed: May 9, 2002
    Publication date: April 17, 2003
    Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Mike Roof, Kelly Burkhart, David E. Gorcyca
  • Patent number: 6498008
    Abstract: The invention includes a vaccine and sera for treatment of Mystery Swine Disease (MSD), a method for producing the vaccine, methods for diagnosis of MSD, a viral agent that will mimic “mystery swine disease” and antibodies to the viral agent useful in diagnosis and treatment of MSD. The serum contains mammalian antibodies which are effective in treating MSD.
    Type: Grant
    Filed: December 18, 2000
    Date of Patent: December 24, 2002
    Assignees: Regents of the University of Minnesota, South Dakota State University, Boehringer Ingelheim Vetmedica, Inc.
    Inventors: James E. Collins, David A. Benfield, Danny W. Chladek, Louis L. Harris, David E. Gorcyca
  • Patent number: 6241990
    Abstract: The invention includes a vaccine and sera for treatment of Mystery Swine Disease (MSD), a method for producing the vaccine, methods for diagnosis of MSD, a viral agent that will mimic “mystery swine disease” and antibodies to the viral agent useful in diagnosis and treatment of MSD. The serum contains mammalian antibodies which are effective in treating MSD.
    Type: Grant
    Filed: January 31, 2000
    Date of Patent: June 5, 2001
    Assignees: Regents of the University of Minnesota, South Dakota State University, Boehringer Ingelheim Vetmedica, Inc.
    Inventors: James E. Collins, David A. Benfield, Danny W. Chladek, Louis L. Harris, David E. Gorcyca
  • Patent number: 6110468
    Abstract: The invention includes a vaccine and sera for treatment of Mystery Swine Disease (MSD), a method for producing the vaccine, methods for diagnosis of MSD, a viral agent that will mimic "mystery swine disease" and antibodies to the viral agent useful in diagnosis and treatment of MSD. The serum contains mammalian antibodies which are effective in treating MSD.
    Type: Grant
    Filed: September 11, 1997
    Date of Patent: August 29, 2000
    Assignees: Regents of the University of Minnesota, South Dakota State University, Boechringer Ingelheim Vetmedica, Inc.
    Inventors: James E. Collins, David A. Benfield, Danny W. Chladek, Louis L. Harris, David E. Gorcyca
  • Patent number: 6080570
    Abstract: The invention includes a vaccine and sera for treatment of Mystery Swine Disease (MSD), a method for producing the vaccine, methods for diagnosis of MSD, a viral agent that will mimic "mystery swine disease" and antibodies to the viral agent useful in diagnosis and treatment of MSD. The serum contains mammalian antibodies which are effective in treating MSD.
    Type: Grant
    Filed: September 10, 1997
    Date of Patent: June 27, 2000
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Danny W. Chladek, Louis L. Harris, David E. Gorcyca